How does somatic BRCA testing influence treatment decisions in addition to germline results?

How does somatic BRCA testing influence treatment decisions in addition to germline results?

• A. It has no impact
• B. Somatic BRCA alterations can indicate suitability for PARP inhibitors or platinum-based therapy even when germline results are negative
• C. It only affects screening intervals
• D. It negates germline findings

Answer: (B)

Somatic BRCA testing looks at the tumor’s BRCA genes and reveals homologous recombination deficiency within cancer cells. This deficiency makes tumor cells particularly vulnerable to PARP inhibitors and platinum-based chemotherapy, because these treatments exploit that repair weakness. Importantly, this guidance comes from the tumor's biology and can be relevant even if germline testing is negative, meaning the inherited risk isn’t driving the therapy choice in that case. Germline results still matter for assessing hereditary cancer risk and family planning, but they don’t negate or override somatic findings. So somatic BRCA alterations can indicate suitability for PARP inhibitors or platinum-based therapy regardless of germline results.

Somatic BRCA testing looks at the tumor’s BRCA genes and reveals homologous recombination deficiency within cancer cells. This deficiency makes tumor cells particularly vulnerable to PARP inhibitors and platinum-based chemotherapy, because these treatments exploit that repair weakness. Importantly, this guidance comes from the tumor's biology and can be relevant even if germline testing is negative, meaning the inherited risk isn’t driving the therapy choice in that case. Germline results still matter for assessing hereditary cancer risk and family planning, but they don’t negate or override somatic findings. So somatic BRCA alterations can indicate suitability for PARP inhibitors or platinum-based therapy regardless of germline results.